La FDA approuvera-t-elle le deramiocel dans la dystrophie musculaire de Duchenne avant le 30 novembre 2026 ?

• Ce qui fait monter. The FDA extended the PDUFA date to November 22, 2026, to review 24-month open-label extension data rather than issuing an immediate rejection, suggesting the data is under active consideration [0].
• Ce qui fait monter. The sponsor reported positive 24-month HOPE-3 data, which they claim supports the preservation of upper-limb function [6, 7].
• Ce qui fait monter. Data from the HOPE-3 trial was published in The Lancet, providing a degree of peer-reviewed validation for the study's findings [2].
• Ce qui fait monter. The indication has been reframed to a more specific endpoint (preservation of upper-limb function), which can sometimes facilitate a clearer path to approval in rare diseases [Starting State].
• Ce qui fait descendre. The application has a history of significant regulatory friction, including one CRL and two prior delays [Starting State].
• Ce qui fait descendre. The PDUFA date of November 22 is only eight days before the resolution deadline, leaving almost no margin for further administrative delays or a third postponement [Starting State].
• Ce qui fait descendre. Market reports suggest that the 24-month OLE data may not have fully addressed existing regulatory concerns, leading to investor skepticism [5].
• Ce qui fait descendre. The classification of the OLE data as a 'major amendment' indicates that the initial submission was insufficient for approval [0].
• Ce qui ferait le plus bouger ce chiffre. The FDA's interpretation of the 24-month open-label extension data and whether it provides the 'substantial evidence of effectiveness' required to overcome the deficiencies noted in the previous CRL.

• Ce qui fait monter. The FDA accepted the submission of 24-month open-label extension data from the HOPE-3 trial as a major amendment and set a new PDUFA date of 22 November 2026, indicating active review rather than immediate rejection [1].
• Ce qui fait monter. Capricor reported positive 24-month HOPE-3 data for deramiocel, supporting the reframed indication around preservation of upper-limb function [4].
• Ce qui fait descendre. The application has a history of regulatory hurdles, having already received one CRL and two delays [1].
• Ce qui fait descendre. The margin of error is extremely small, with only 8 days between the PDUFA date (22 November 2026) and the resolution deadline (30 November 2026); any further delay or a CRL will result in a 'No' [1].
• Ce qui fait descendre. Tier 4 reports indicate that the 24-month data may not have fully resolved regulatory concerns, causing a drop in stock price [4].
• Ce qui ferait le plus bouger ce chiffre. Whether the FDA finds the 24-month HOPE-3 open-label extension data sufficient to support approval for the reframed indication without requiring further clinical trials or causing another delay.

• Ce qui fait monter. PDUFA target date set for 22 Nov 2026, which is before the deadline, indicating FDA intends to decide by then [tier 1]
• Ce qui fait descendre. Application has already received a complete response letter and two prior delays, suggesting regulatory concerns [tier 1]
• Ce qui fait descendre. FDA classified the 24‑month extension data as a "major amendment", implying additional scrutiny [tier 1]
• Ce qui ferait le plus bouger ce chiffre. Whether the FDA will resolve the outstanding issues raised in the complete response letter before the PDUFA date

Raisons non conservées pour cette révision (l'historique détaillé n'est gardé que depuis peu).

Raisons non conservées pour cette révision (l'historique détaillé n'est gardé que depuis peu).

Raisons non conservées pour cette révision (l'historique détaillé n'est gardé que depuis peu).